Glioblastoma Inhibiting Compounds and Their Use

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention pertains to new compounds, particularly gambogic acid amide and its derivatives, that are designed to inhibit and treat glioblastoma, one of the most aggressive types of brain tumors. The patent includes the use of these compounds as pharmaceuticals and also describes methods to determine which patients are likely to benefit from these treatments based on specific markers, such as overexpression of CD133 in tumor cells. These compounds have shown potent effects against glioblastoma cells, including those with stem-like properties, and may work across various genetic variations of glioblastoma.

Use CasesContent extracted from patent full text and abstract with AI.

• Pharmaceutical treatment of glioblastoma in adult patients, including both primary and recurrent forms.
• Personalized medicine: Selecting patients most likely to respond to gambogic acid amide therapy based on tumor biomarkers like CD133.
• Therapies targeting glioblastoma stem-like cells to overcome resistance and recurrence.
• Combination treatments: Using gambogic acid amide along with current standard-of-care drugs like temozolomide to potentially improve outcomes.
• Development of diagnostic kits to assess suitability for treatment based on gene expression analysis in tumor biopsies.
• Use in preclinical glioblastoma research for investigating mechanisms of action or identifying new drug combinations.

BenefitsContent extracted from patent full text and abstract with AI.

• Targets both the bulk tumor and the resistant stem-like subpopulation in glioblastoma, which are thought to drive recurrence.
• Shows activity across various genetic and molecular subtypes of glioblastoma, making it broadly applicable.
• Demonstrates stronger anti-glioblastoma effects in cell studies compared to many current drugs, including temozolomide.
• Selectivity for cancer stem cells (CD133+), offering the potential to reduce recurrence and improve long-term survival.
• Personalized approach allows for better targeting and potential treatment effectiveness based on tumor biomarkers.
• Can be combined with existing therapies to enhance anti-tumor effects.
• Offers new hope for a cancer type with currently poor prognosis and limited therapy options.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to glioblastoma inhibiting compounds, in particular gambogic acid amid and derivatives thereof for the treatment of glioblastoma. Moreover, methods for determining whether a treatment with the compounds of the invention is suitable for a patient are disclosed.